Cardiology, Severe Hypertension, Clinical Trials, Tonlamarsen

Cardiology, Severe Hypertension, Clinical Trials, Tonlamarsen

Tonlamarsen's KARDINAL Failure Reveals a Hidden Acute Care Opportunity in Severe Hypertension

Deep upstream RAAS silencing demonstrates remarkable renal safety but hits definitive hemodynamic limits in chronic uncontrolled populations, requiring a strategic pivot toward inpatient acute bridging. See Disclaimer below * Introduction Acute Severe Hypertension (ASH) represents one of cardiovascular medicine's most dangerous and underserved emergencies. Affecting approximately 300,000 to